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ABSTRACT: The genetic factors that contribute to the development of chronic obstructive
pulmonary disease (COPD) are poorly understood. Many candidate genes have been proposed,
including enzymes that protect the lung against oxidative stress, such as microsomal epoxide
hydrolase (EPHX1) and glutamate-cysteine ligase (GCL). To date, most reported findings have
been for EPHX1, particularly in relation to functional variants associated with fast and slow
metabolism of epoxide intermediates. The present study aimed to identify any association of
variation in these genes with COPD susceptibility or severity.
In total, 1,017 white COPD patients and 912 nondiseased age and sex matched smoking
controls were genotyped for six single nucleotide polymorphisms (SNPs) in EPHX1 (including the
fast and slow variants and associated haplotypes), and eight SNPs in the two genes encoding
GCL. GCL is a rate-limiting enzyme in the synthesis of glutathione, a major contributor to anti-
oxidant protection in the lung.
No association of variation was found in EPHX1 or GCL with susceptibility to COPD or disease
severity.
This is the largest reported study to date and is well powered to detect associations that have
been previously suggested. The current data indicate that these genetic variants are unlikely to be
related to susceptibility or disease severity in white chronic obstructive pulmonary disease
patients.
KEYWORDS: Chronic obstructive pulmonary disease, genetic susceptibility, glutamate-cysteine
ligase, microsomal epoxide hydrolase
C
hronic obstructive pulmonary disease
(COPD) is the sixth leading cause of
morbidity and mortality in the western
world and the prevalence of the disease is
increasing as the population ages [1]. Cigarette
smoking is the major environmental contributor
to the disease in western societies yet only ,15%
of cigarette smokers develop the disease, indicat-
ing that genetic factors play a part in determining
susceptibility. With the notable exception of
severe a1-antitrypsin (a1-AT) deficiency, these
genetic factors are poorly understood.
Given that .95% of those who develop COPD
are smokers and oxidative stress is thought to be
important in the pathogenesis of the disease,
genetic variation in enzymes that protect the lung
against smoke-induced oxidative stress has been
a significant focus of study. Microsomal epoxide
hydrolase (EPHX1), an enzyme involved in the
first-pass metabolism of epoxide intermediates,
has received particular attention as two func-
tional variants of the gene, which confer slow and
fast metabolic activity, have been identified [2].
The slow variant decreases activity by ,40–50%,
whilst the fast variant increases activity by,25%.
Since the initial report of an association between
increased susceptibility to COPD and His-His
homozygosity at the ‘‘slow’’ variant locus
(Tyr113His in exon 3) [3], subsequent studies
have variously supported this association [4–6],
or have reported an association with disease
severity rather than susceptibility [7]; observed
no association between this polymorphism and
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disease susceptibility or severity [8–10]; or reported a
protective effect of this polymorphism [11]. Similar disparities
in study outcomes are reported for the ‘‘fast’’ variant
(His139Arg in exon 4) with possession of the minor variant
reported as being associated with protection [12, 13] or having
no effect [3, 11].
The lack of replication and inconsistency in these studies most
likely reflect a range of issues that can produce false-positive or
false-negative outcomes in case–control studies of complex
diseases where relatively weak associations between single
genes and disease are expected [14]. These include lack of
power due to insufficient numbers of cases and controls, poor
matching of cases and controls, particularly for smoking [15],
and genetic heterogeneity in and between different study
populations. A recent study has also shown that, when using
restriction fragment length polymorphism (RFLP) techniques,
genotyping error arising from the presence of a single
nucleotide polymorphism (SNP) at Lys119 near the exon 3
slow polymorphism can lead to significant overestimation of
His113 homozygotes [10] with resulting lack of Hardy–
Weinberg (HW) equilibrium in study populations. Indeed, in
a meta-analysis of previous studies in which populations that
were not in HW equilibrium were omitted, His113 homo-
zygosity was reported as being protective against the develop-
ment of COPD [11].
To address many of these issues, in a previous study the
present authors collected samples from a cohort of 1,017 white
COPD patients and 912 nondiseased control smokers, matched
for ethnicity, age and sex [16]. This represented the largest
collection reported to date in a candidate gene approach. By
matching cases and controls from each centre in Europe the
risk of population stratification was minimised. Recent data
from genome-wide association studies have shown that, at
least in the British population, there is very little evidence for
stratification in nearly 3,000 controls analysed to date. A
relatively small number of genes showed significant differ-
ences in allele frequencies, suggesting that the population is
relatively homogeneous and not as variable as previously
thought [17]. In the current study this resource was used to
evaluate the relationship between EPHX1 variants with respect
to both the occurrence and severity of COPD. The association
between genetic variation in glutamate-cysteine ligase (GCL;
also known as c-glutamyl-cysteine synthetase) and risk of
developing COPD was assessed. This is the rate-limiting
enzyme in the synthesis of glutathione, a central contributor to
the lung’s anti-oxidant defence system. Recently, variation in
the catalytic subunit of the gene has been shown to be associated
with lung disease severity in cystic fibrosis [18]. To date, genetic
variation in this gene has only been reported in one small study
of COPD in which no association was found [19].
MATERIALS AND METHODS
Subjects
COPD cases and control subjects were recruited at six
European centres. The number of subjects recruited from each
centre was as follows. Barcelona (Spain): 70 controls and 138
cases; Bristol (UK): 152 controls and 129 cases; Dublin
(Ireland): 195 controls and 196 cases; Edinburgh (UK): 81
controls and 168 cases; Leiden (the Netherlands): 216 controls
and 188 cases; and Pisa (Italy): 198 controls and 198 cases.
Approval for the study was obtained from the appropriate
committees at each recruitment centre. Informed consent was
obtained from all subjects. Criteria for patient recruitment
were: a firm clinical diagnosis of stable COPD; airflow
limitation as indicated by forced expiratory volume in one
second (FEV1) f70% normal predicted values; FEV1/forced
vital capacity (FVC) ,70% pred; no significant reversibility on
bronchodilation; and a smoking history of o20 pack-yrs.
Patients were excluded from the study if they had an
established diagnosis of asthma, lung cancer, a history of
atopy, known a1-AT deficiency or a serum a1-AT level
,1.0 g?L-1. Subjects were also excluded if they had had an
acute exacerbation in the 4 weeks preceding assessment for the
study.
Control subjects were recruited at each centre to match COPD
patients for ethnicity, age, sex and smoking history. Exclusion
criteria were as described for cases and also included a family
history of COPD. Only individuals with no evidence of airflow
obstruction (FEV1 and FVC o80% and FEV1/FVC .70%) were
included in the control group. Only white subjects were
recruited for cases and controls. Complete matching between
cases and controls was not achieved, but this was taken into
account during the analysis.
No previous evidence has been found for population stratifica-
tion in this sample set, in keeping with the data obtained from
a large sample of the British population [16, 17].
SNP mapping and haplotypes
DNA sequencing to identify SNPs was carried out using a
previously described approach [16]. Primers were designed for
PCR so that the exons and flanking regions of the genes could
be screened. These SNPs were then genotyped using Taqman
assays (Applied Biosystems, Foster City, CA, USA) in 291
independent samples from white subjects from a previous
study of COPD to obtain more robust data on the frequencies
of SNPs. All subjects had given informed consent and the
study was approved by the ethics committee of each recruiting
centre. Where SNPs were in full linkage disequilibrium in the
sequenced samples, a single representative SNP was chosen
for genotyping. Where the minor allele frequency of SNP fell
below 5% it was removed from further analyses.
Genotyping of study samples
Genotyping of the study population for six SNPs in the EPHX1
gene and eight SNPs in the GCL genes (five in the GCL
catalytic (GCLC) and three in the GCL modifier (GCLM)
subunits) was carried out at Geneservices Ltd (Cambridge,
UK) using Taqman assays. Primer and probe sequences are
available on request. As a quality control measure, the 44
samples of known genotype from sequencing were included.
These genotypes were unknown to Geneservices Ltd but were
used as an internal quality control measure. If discrepancies
were noted the analysis was repeated; this resulted in 100%
concordance for all the assays.
Statistical analysis
Analysis of genetic variation in population groups
Each of the SNPs in the three genes were analysed for HW
equilibrium. To examine linkage disequilibrium, the correlation
coefficient between SNP pairs within each gene in cases and
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controls was calculated. As matching was not completely
achieved on recruitment, allele and genotype frequencies were
adjusted for any residual confounding due to age, sex, smoking
and centre using logistic regression. This also gave an increase
in power by accounting for the matched design. Interactions of
age, sex and smoking with centre were included as previously
described [16]. Due to the study size it was possible to detect
small differences between cases and controls. For instance, over
the SNPs investigated, the (rare-type) allele frequency in
controls ranged from a low of 7.4% to a high of 26.6% (both
SNPs being in the GCL gene; tables 1 and 2). Using these
extremes as examples and taking a 1% two-sided level of
significance, the study had a power of 95% to detect an allele
frequency of o11.4% in the cases compared with 7.4% in
controls, and a frequency of o32.8% compared with 26.6%. The
corresponding detectable percentages for a lower frequency in
cases than controls are 4.2 and 20.8%, respectively.
Haplotype analysis
For full analysis of the relationships between COPD and
EPHX1 and GCL variants, a staged, haplotype-based approach
was used, as described previously [16]. First, the SNP group-
ings on which to perform the haplotype analysis were
identified. To allow for any combination, the present authors
screened all the possible SNP groups in the EPHX1 gene and in
the GCLM and GCLC genes for differences between cases and
controls. This was carried out by performing an omnibus test
[20] and employing a p-value of ,0.01 as a cut-off value for
statistical significance. Exact p-values based on 10,000 permu-
tations were generated. Extremely rare haplotypes, occurring
at a frequency of ,1% within each of these groups, were
excluded. Individual haplotypes were compared between
COPD cases and controls using the pseudo Chi-squared test.
A 1% level of significance was taken.
RESULTS
Characteristics of the study population
The characteristics of the control and COPD groups recruited
to the study are summarised in table 3. Targeted recruitment
of controls yielded groups with similar age and sex profiles,
although complete matching of control and COPD groups was
not achieved as a high proportion of smokers aged .65 yrs
had evidence of some obstruction in pulmonary function and
were therefore excluded from recruitment as controls. This
incomplete matching was adjusted for in the analysis of the
data. Within the COPD group, those recruited were almost
equally distributed across the Global Obstructive Lung Disease
severity categories of moderate, severe and very severe (see
table 1S of online supplementary data).
SNP mapping
EPHX1
In total, 25 SNPs were identified in the EPHX1 gene on
sequencing (see table 2S of online supplementary data). Two
of these SNPs (rs45616640 and rs45505095) had a minor allele
frequency of ,5% so were excluded from further analysis. Two
further SNPs (rs45467394 and rs4149227) were unsuitable for
Taqman assay design. Complete linkage disequilibrium was
observed between SNPs at sites -699/-613/-362 and -290/-200 in
the 59 flanking region leaving 19 SNPs with poor linkage
disequilibrium occurring at a frequency of .5%. As screening
for 19 SNPs would result in a large number of haplotypes
occurring at a frequency ,1%, thus reducing the power of the
study, a selection of six SNPs was made based on either
previous associations or with potential functional variants. The
SNPs chosen included three that fully covered variation in the
promoter region (rs2854450, rs2854451 and rs3753658), the slow
and fast functional SNPs (rs1051740 and rs2234922, respectively)
that have been shown to affect activity of EPHX1 and one SNP
(rs4653695) from the 39 untranslated end of the gene.
GCL
Six SNPs were identified in the GCLC subunit and six in the
GCLM subunit. The location and nucleotide substitution of
these SNPs are indicated in the supplementary data (table 3S).
In the GCLC subunit, two SNPs (rs2100375 and rs1901773)
were in complete linkage disequilibrium, so only the rs2100375
was assessed in further analyses. In 291 independent samples,
the remaining five SNPs were found to contribute to nine
haplotypes that occurred with a frequency of .1% and
accounted for 99% of the observed variation in the gene, thus,
providing almost complete coverage of the gene. These five
SNPs were genotyped in the study population. In the GCLM
subunit, three SNPs (rs41303970, rs743119 and rs2273406) were
in complete linkage disequilibrium, so rs41303970 was chosen
to infer information for all three sites in subsequent analyses.
SNP rs35267053 had a minor allele frequency of ,5%, so was
not included in further investigations. The three remaining
SNPs were found to contribute to four haplotypes that
occurred with a frequency of .1% and accounted for 99% of
the observed variation in the 291 samples screened. All three
SNPs were genotyped in the final sample resource.
Analysis of variation in EPHX1 and GCL genes in COPD and
controls
The allele and genotype frequencies of the six EPHX1 SNPs
that were screened in the full study population are shown in
TABLE 1 Glutamate-cysteine ligase (GCL) allele
frequencies in controls and chronic obstructive
pulmonary disease (COPD) subjects
SNP no. SNP dbSNP
reference
Control COPD p-value
Crude Corrected#
GCLC
1c C-129T rs17883901 0.074 0.068 0.48 0.67
2c G24434A rs2100375 0.279 0.277 0.86 0.65
3c G36138A rs16883912 0.102 0.102 0.95 0.41
4c A37764G rs1555903 0.091 0.087 0.62 0.58
5c G39514A rs524553 0.222 0.231 0.50 0.15
GCLM
1m C-590T rs41303970 0.159 0.152 0.62 0.30
2m C7623T rs7515191 0.354 0.336 0.26 0.21
3m G14613T rs769211 0.266 0.250 0.29 0.25
SNP: single nucleotide polymorphism; dbSNP: SNP database; GCLC: GCL
catalytic subunit; GCLM: GCL modifier subunit. #: adjusted by logistic
regression for age, sex, centre and smoking.
S. CHAPPELL ET AL. EPHX1 AND GCL VARIATION IN COPD
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 32 NUMBER 4 933
tables 4–6. For ease of presentation, screened SNPs are
numbered sequentially from 1 to 6 with the gene location
relative to the transcription start site, base substitution and the
National Centre for Biotechnology Information SNP database
(dbSNP) reference number for each SNP indicated. All of the
SNPs were within the accepted criteria for HW equilibrium
and the frequencies of the SNPs were similar in the popula-
tions from all six recruitment centres.
No difference in allele frequency was observed between
patient and control groups for any individual EPHX1 SNP
nor was there any difference (at the 1% level set for acceptance
of significance) in SNP genotype frequencies between patients
and controls (table 4–6). Similarly, when classified into func-
tional phenotypes on the basis of genotype at the slow and fast
loci, as described by SMITH and HARRISON [3], no difference was
observed between controls and COPD patients. Neither were
functional phenotypes found to be associated with disease
severity within the cases (see table 4S of online supplementary
data). The common six SNP haplotypes (occurring with a
frequency .1%) associated with the slow and fast functional
variants were also evaluated, but no difference was found in
haplotypes between control and COPD groups (table 7).
As with the EPHX1 gene, the frequencies of the six SNPs
screened in the GCLC and GCLM genes were similar in the
populations from all six recruitment centres and, with the
exception of SNP 1m (C-590T GLCM subunit), all were within
the accepted criteria for HW equilibrium. For SNP 1m, the
frequency of the minor allele homozygotes was slightly higher
than expected (4.3 versus 2.5%) in the control population
(p50.002). This was unlikely to be due to genotyping error as
the blinded controls for this assay were accurately assigned.
The frequency of the minor allele is ,5% and small deviations
in observed numbers may cause significant deviation from
HW equilibrium. The possibility of a copy number variant,
which often contributes to deviations from HW equilibrium,
cannot be fully excluded although no evidence for this was
found in preliminary experiments using real-time PCR (data
not shown).
No difference in allele frequency was observed between case
and control groups for any individual SNP in either the GCLC
or GCLM genes, nor was there any difference in SNP genotype
frequencies (tables 1 and 2).
Linkage disequilibrium analysis (see tables 5S and 6S in the
online supplementary data) demonstrated strong linkage
between SNPs 2c and 5c (rs2100375 and rs524553) in the
GCLC subunit and between all three SNPs in the GCLM
subunit in both case and control groups. No strong linkage was
observed between SNPs evaluated in the EPHX1 gene in either
cases or controls.
Haplotype analysis of SNP combinations in each of the three
genes did not identify any combinations that were related to
COPD. Similarly, when evaluated on the basis of disease
severity within the COPD group, no association between
haplotypes and disease severity was observed for any of the
three genes evaluated.
DISCUSSION
The EPHX1 gene has been a significant focus for studies on
genetic susceptibility in COPD in the past 10 yrs. It is a
promising candidate gene as it is strongly expressed in the
TABLE 2 Glutamate-cysteine ligase (GCL) genotype frequencies in controls and chronic obstructive pulmonary disease (COPD)
subjects
SNP no. SNP ID Genotype Control COPD p-value
Crude Corrected#
GCLC
1c C129T CC/CT/TT 0.86/0.14/0.004 0.87/0.12/0.01 0.41 0.22
2c G24434A GG/GA/AA 0.54/0.37/0.09 0.51/0.42/0.07 0.02 0.12
3c G36138A GG/GA/AA 0.80/0.19/0.01 0.81/0.18/0.01 0.57 0.19
4c A37764G AA/AG/GG 0.82/0.17/0.004 0.84/0.16/0.01 0.29 0.14
5c G39514A GG/GA/AA 0.61/0.34/0.05 0.58/0.39/0.04 0.07 0.05
GCLM
1m C-590T CC/CT/TT 0.73/0.23/0.04 0.73/0.24/0.03 0.42 0.31
2m C7623T CC/CT/TT 0.43/0.44/0.13 0.44/0.45/0.11 0.34 0.42
3m G14613T GG/GT/TT 0.54/0.39/0.07 0.56/0.39/0.06 0.38 0.42
SNP: single nucleotide polymorphism; GCLC: GCL catalytic subunit; GCLM: GCL modifier subunit. #: adjusted by logistic regression for age, sex, centre and smoking.
TABLE 3 Characteristics of control and chronic obstructive
pulmonary disease (COPD) study subjects
Control COPD p-value
Subjects n 912 1017
Male % 63.6 69.8 0.0038
Age yrs 60.8¡8.9 65.9¡8.2 ,0.0001
Smoking pack-yrs 38.7¡17.4 48.7¡22.8 ,0.0001
FEV1 % pred 95.4¡11.0 43.2¡15.2 ,0.0001
FEV1/FVC 77.8¡4.9 47.6¡12.1 ,0.0001
Data are presented as mean¡ SD, unless otherwise stated. FEV1: forced
expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity.
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bronchial epithelium and its biological role in detoxifying
epoxides is extremely relevant in protecting the lung against
smoke-induced damage. In addition, there is significant indivi-
dual variation in enzymatic activity, and genetic polymorphisms
that modify enzymatic activity have been identified [21].
The majority of studies on genetic variants of EPHX1 in COPD
have evaluated polymorphisms in the coding region of the gene
that are associated with slow (Tyr113His) and fast (His139Arg)
enzymatic activity, with conflicting results. Many of these
studies have limitations with respect to power (with numbers of
subjects in the case and control groups ranging 60–200);
matching for ethnicity, age, sex and smoking history also vary
considerably. In addition, studies that analysed polymorphic
variation using RFLP techniques are likely to have over-
estimated the proportion of slow (113His) homozygotes [10].
The present study overcomes many of these limitations by
evaluating EPHX1 polymorphisms in case and control groups
with sufficient power to readily replicate previously reported
associations. All subjects were white and any potential effects
of population stratification were minimised by recruiting cases
and controls from the same populations. In addition, targeted
recruitment of controls facilitated the enrolment of controls
with a similar profile to COPD patients with respect to sex, age
and smoking.
Analysis of EPHX1 polymorphisms showed no relationship
between susceptibility to COPD and variation at the Tyr113His
or His139Arg loci. Given the significantly greater level of power
and case–control matching in the present study it is unlikely that
effects of the magnitude observed in previous, less powered
studies have been missed. All EPHX1 SNPs evaluated were in
HW equilibrium in control populations. This, along with the
inclusion of previously sequenced samples as quality controls in
the genotyping analysis, indicates that the current analysis is not
affected by genotyping error.
Furthermore, detailed analysis of haplotypes corresponding to
the fast (His139Arg) and slow (Tyr113His) variants failed to
identify haplotypes that were associated with disease. The
present authors also analysed variation in the 59 promoter
region of the EPHX1 gene, which has been shown to modulate
enzyme expression by up to 30% [21], but no association with
disease susceptibility was found.
The current results are at variance with two adequately
powered recent studies which report the protective effects of
the His139Arg [12] and Try113His [11] alleles, although neither
study replicated the other’s results. In a study of 304
emphysema patients and 441 controls, HERSH et al. [12] report
a protective effect (odds ratio 0.73, p50.03) with the fast
variant of codon 139, while no association was observed with
variation in the 113 codon. By contrast, BROGGER et al. [11]
evaluated the same polymorphisms in 492 white smokers and
ex-smokers (244 COPD patients and 248 controls) and reported
a protective effect of His/His homozygosity at the 113 locus,
with no effect of variation at the 139 locus. The present study
did not replicate either of these observations, nor were they
noted in the majority of the smaller studies [3–10].
Sequencing of the EPHX1 gene revealed that variation in this
gene is high, with 25 polymorphisms being identified. This may
explain some of the conflicting results reported in studies of the
slow and fast variants as these polymorphisms could contribute
to disease susceptibility on a background of other specific SNP
variants or haplotypes. However, this seems unlikely as the
present authors have captured the most significant haplotypes
corresponding to the fast and slow variants. It may be that
variation in other genes plays a role as studies on the impact of
the slow and fast EPHX1 genetic variants indicate that they may
have only a modest impact on in vivo activity levels and that
TABLE 4 Microsomal epoxoide hydrolase minor allele
frequencies in controls and chronic obstructive
pulmonary disease (COPD) subjects
SNP
no.
SNP ID dbSNP
reference
Control COPD p-value
Crude Corrected#
1 C-399T rs2854450 0.217 0.206 0.40 0.30
2 G-362A rs2854451 0.245 0.242 0.82 0.95
3 G-290T rs3753658 0.124 0.132 0.43 0.63
4 T6651C rs1051740 0.301 0.294 0.60 0.86
5 A13426G rs2234922 0.204 0.208 0.76 0.90
6 A20094C rs4653695 0.107 0.111 0.65 0.91
SNP: single nucleotide polymorphism; dbSNP: SNP database. #: adjusted by
logistic regression for age, sex, centre and smoking.
TABLE 5 Microsomal epoxoide hydrolase genotype frequencies in controls and chronic obstructive pulmonary disease (COPD)
subjects
SNP no. SNP ID Genotype Genotype frequency p-value
Control COPD Crude Corrected#
1 C-399T CC/CT/TT 0.62/0.33/0.05 0.63/0.33/0.04 0.50 0.17
2 G-362A GG/GA/AA 0.57/0.36/0.06 0.58/0.35/0.07 0.83 0.98
3 G-290T GG/GT/TT 0.77/0.21/0.02 0.75/0.23/0.02 0.27 0.12
4 T6651C TT/TC/CC 0.49/0.41/0.10 0.50/0.41/0.09 0.80 0.98
5 A13426G AA/AG/GG 0.64/0.31/0.05 0.63/0.33/0.04 0.72 0.97
6 A20094C AA/AC/CC 0.80/0.19/0.01 0.79/0.21/0.01 0.30 0.43
SNP: single nucleotide polymorphism. #: adjusted by logistic regression for age, sex, centre and smoking.
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post-transcriptional modification may be important [21–23].
Therefore, it seems unlikely that these particular variants
contribute to COPD susceptibility, although the possibility of
rare variants playing a role cannot be excluded and significantly
larger studies are needed to test this reliably.
The rate limiting enzyme in glutathione synthesis, GCL, is also
a potential candidate gene for susceptibility to COPD.
Significantly decreased glutathione levels are observed in the
lungs of GCLM knockout mice [24] and message expression for
this subunit is decreased in alveolar macrophages from healthy
smokers [25]. In addition, the presence of GCL protein in the
bronchial airways appears to be diminished in smokers and
COPD patients compared with nonsmoking controls [26, 27].
Both subunits of this enzyme were genotyped and investigated
with the role of the genetic variation observed as a potential
risk factor for disease. As with EPHX1, no association was
found with disease and SNPs in genes encoding either subunit
of the GCL enzyme. This confirms the only other reported
study of GCL genetic variation in COPD, which investigated a
single SNP in the GCLC gene (rs17883901; SNP 1c) in 322
subjects from the Han Chinese population, and failed to find
evidence for an association with COPD [19]. The present study
has extended these previous findings to include more SNPs
throughout the GCLC gene, as well as considering variation in
the gene for the GCLM subunit.
In conclusion, no evidence was found for a significant
association of polymorphisms in microsomal epoxide hydro-
lase or glutamate-cysteine ligase with susceptibility to chronic
obstructive pulmonary disease in a white population.
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